X0M1 Stock Overview
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
XOMA Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$23.80 |
| 52 Week High | US$24.20 |
| 52 Week Low | US$12.70 |
| Beta | 0.59 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | 43.37% |
| 3 Year Change | -21.71% |
| 5 Year Change | 119.80% |
| Change since IPO | -75.96% |
Recent News & Updates
Recent updates
Shareholder Returns
| X0M1 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -1.7% | -5.1% | -2.0% |
| 1Y | 43.4% | -21.1% | -0.3% |
Return vs Industry: X0M1 exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: X0M1 exceeded the German Market which returned -0.3% over the past year.
Price Volatility
| X0M1 volatility | |
|---|---|
| X0M1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.0% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: X0M1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine X0M1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 13 | Owen Hughes | www.xoma.com |
XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.
XOMA Corporation Fundamentals Summary
| X0M1 fundamental statistics | |
|---|---|
| Market cap | €278.32m |
| Earnings (TTM) | -€43.47m |
| Revenue (TTM) | €4.47m |
62.3x
P/S Ratio-6.4x
P/E RatioIs X0M1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| X0M1 income statement (TTM) | |
|---|---|
| Revenue | US$4.76m |
| Cost of Revenue | US$143.00k |
| Gross Profit | US$4.62m |
| Other Expenses | US$50.92m |
| Earnings | -US$46.30m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.98 |
| Gross Margin | 96.99% |
| Net Profit Margin | -973.16% |
| Debt/Equity Ratio | 139.8% |
How did X0M1 perform over the long term?
See historical performance and comparison